Search

NXN-188

NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

VB2-011

VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

Barbexaclone

Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009. … These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials.

TAS-106

TAS-106 has demonstrated strong antitumor activity without serious toxicity in nude rat models bearing human tumours [A31693].

ACE393

ACE393 is an injectable vaccine designed to combat the bacterium Campylobacter jejuni, one of the greatest causes of bacterial diarrhoeal infections in the developed world.

Tubercidin

An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids

Diaziquone

Phosphocysteamine

1D09C3

1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … The antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC

MB-07803

It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.